KR101035053B1 - 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신 - Google Patents

감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신 Download PDF

Info

Publication number
KR101035053B1
KR101035053B1 KR1020087001874A KR20087001874A KR101035053B1 KR 101035053 B1 KR101035053 B1 KR 101035053B1 KR 1020087001874 A KR1020087001874 A KR 1020087001874A KR 20087001874 A KR20087001874 A KR 20087001874A KR 101035053 B1 KR101035053 B1 KR 101035053B1
Authority
KR
South Korea
Prior art keywords
vaccine
ala
arg
mycobacterium
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087001874A
Other languages
English (en)
Korean (ko)
Other versions
KR20080027877A (ko
Inventor
클라우스 아가르드
카리나 빙스보-룬드베르그
피터 안데르센
Original Assignee
스태튼스 세룸 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스태튼스 세룸 인스티튜트 filed Critical 스태튼스 세룸 인스티튜트
Publication of KR20080027877A publication Critical patent/KR20080027877A/ko
Application granted granted Critical
Publication of KR101035053B1 publication Critical patent/KR101035053B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087001874A 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신 Expired - Fee Related KR101035053B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200500924 2005-06-23
DKPA200500924 2005-06-23
DKPA200501393 2005-10-05
DKPA200501393 2005-10-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020107024618A Division KR101188045B1 (ko) 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신

Publications (2)

Publication Number Publication Date
KR20080027877A KR20080027877A (ko) 2008-03-28
KR101035053B1 true KR101035053B1 (ko) 2011-05-19

Family

ID=37134239

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087001874A Expired - Fee Related KR101035053B1 (ko) 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신
KR1020107024618A Expired - Fee Related KR101188045B1 (ko) 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107024618A Expired - Fee Related KR101188045B1 (ko) 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신

Country Status (12)

Country Link
US (4) US7968105B2 (enExample)
EP (4) EP2380589A3 (enExample)
JP (2) JP5219808B2 (enExample)
KR (2) KR101035053B1 (enExample)
CN (1) CN102836425B (enExample)
AU (1) AU2006261445B2 (enExample)
BR (1) BRPI0612833A2 (enExample)
CA (2) CA2612900C (enExample)
ES (1) ES2647070T3 (enExample)
IL (3) IL188222A (enExample)
MX (1) MX2007016165A (enExample)
WO (1) WO2006136162A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529931C1 (de) 1995-08-02 1997-04-03 Mannesmann Ag Plattenkokille zur Erzeugung von Strängen aus Stahl
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
JP5378350B2 (ja) 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物
EP2144626B8 (en) * 2007-04-12 2015-02-18 Mico Bio, Inc. Tuberculosis vaccine and method of using same
BRPI0811796A2 (pt) * 2007-06-26 2020-04-28 Statens Serum Institut Uso de um monomicolil glicerol (mmg) ou de homólogos ou análogos sintéticos e versões modificadas, adjuvante ou imunomodulador, homólogo ou análogo de mmg sintético ou uma versão modificada, vacina e sistema de aplicação
EP2818178A1 (en) 2008-01-11 2014-12-31 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Polypeptide vaccine and vaccination strategy against mycobacterium
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
SI2315773T1 (sl) 2008-07-25 2016-12-30 Glaxosmithkline Biologicals S.A. Polipeptidi, polinukleotidi in sestavki za uporabo pri zdravljenju latentne tuberkuloze
EP2413961B1 (en) * 2009-03-31 2016-08-17 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
TR201903223T4 (tr) * 2009-04-24 2019-03-21 Statens Seruminstitut Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
AU2010277222A1 (en) * 2009-07-29 2012-03-08 Bryce Malcolm Buddle Polymer particles and uses thereof
EP2872172B1 (en) 2012-07-10 2018-11-14 Transgene SA Mycobacterial antigen vaccine
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
RU2520737C1 (ru) * 2013-04-25 2014-06-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА pESAT6-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-DBD, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК ESAT6-DBD И ИХ ПРИМЕНЕНИЕ
RU2539026C1 (ru) * 2013-06-11 2015-01-10 Федеральное государственное бюджетное учреждение "Центральный научно-исследовательский институт туберкулеза" Российской академии медицинских наук РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-CFP10-DBD, РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], СПОСОБ ПОЛУЧЕНИЯ, ИММОБИЛИЗАЦИИ, КОНЦЕНТРИРОВАНИЯ И ОЧИСТКИ РЕКОМБИНАНТНОГО БЕЛКА ESAT6-CFP10-DBD НА ДЕКСТРАНЕ, РЕКОМБИНАНТНЫЙ БЕЛОК ESAT6-CFP10-DBD И ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК ESAT6-CFP10-DBD
CN105431166B (zh) 2013-06-25 2020-09-18 国际艾滋病疫苗行动组织公司 结核病组合物和其使用方法
CA2936131A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
CN107970444B (zh) * 2016-10-25 2022-03-01 中国人民解放军第三0九医院 复合佐剂及含有该复合佐剂的疫苗
BR112021025172A2 (pt) 2019-06-14 2022-01-25 Statens Seruminstitut Proteínas de fusão para vacinas de tuberculose
EP4217066A4 (en) * 2020-09-23 2024-10-23 The General Hospital Corporation BCG VACCINES TO PREVENT COVID-19 AND OTHER INFECTIOUS DISEASES
KR102709729B1 (ko) * 2020-12-04 2024-09-25 주식회사 제넥신 결핵의 예방 또는 치료용 약학적 조성물
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
US20250170236A1 (en) 2022-02-21 2025-05-29 Statens Serum Institut A novel cationic adjuvant composition
CN117531001A (zh) * 2023-11-15 2024-02-09 首都医科大学附属北京胸科医院 结核分枝杆菌毒素抗毒素系统及其相关应用
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004520A2 (en) 2001-07-04 2003-01-16 Health Protection Agency Mycobacterial antigens expressed during latency
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1331C (da) 1897-11-15 Hans Daae Militær- og Skilygte.
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
EP2045261A1 (en) * 1994-09-20 2009-04-08 Hitachi Chemical Co., Ltd. Chlamydia pneumoniae antigenic polypeptides
ES2271954T3 (es) 1995-06-07 2007-04-16 Sanofi Pasteur Inc. Expresion de lipoproteinas.
US20040018574A1 (en) * 1998-08-25 2004-01-29 Marcel Behr Molecular differences between species of the M. tuberculosis complex
PL354982A1 (en) 1999-09-30 2004-03-22 Neurogen Corporation Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
AU2001271963A1 (en) 2000-07-10 2002-01-21 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
WO2002086090A2 (en) * 2001-04-23 2002-10-31 Elitra Pharmaceuticals, Inc. Identification of essential genes of aspegillus fumigatus and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004520A2 (en) 2001-07-04 2003-01-16 Health Protection Agency Mycobacterial antigens expressed during latency
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Microbiol 148(Pt 10): 2967-2973 (2002.10)
Mol Microbiol 43(3): 717-731 (2002)

Also Published As

Publication number Publication date
JP2008543890A (ja) 2008-12-04
WO2006136162A3 (en) 2007-11-15
US20120114687A1 (en) 2012-05-10
US8101193B2 (en) 2012-01-24
US20110206713A1 (en) 2011-08-25
CA2612900A1 (en) 2006-12-28
MX2007016165A (es) 2008-03-14
CA2836319A1 (en) 2006-12-28
US8703151B2 (en) 2014-04-22
CA2612900C (en) 2016-08-09
US7968105B2 (en) 2011-06-28
US20130095132A1 (en) 2013-04-18
JP5219808B2 (ja) 2013-06-26
KR20100122130A (ko) 2010-11-19
EP2380590A3 (en) 2012-08-22
US8293250B2 (en) 2012-10-23
WO2006136162A2 (en) 2006-12-28
EP1910409A2 (en) 2008-04-16
BRPI0612833A2 (pt) 2010-11-30
US20090186048A1 (en) 2009-07-23
IL188222A0 (en) 2008-03-20
JP2013121959A (ja) 2013-06-20
AU2006261445B2 (en) 2011-03-31
KR20080027877A (ko) 2008-03-28
HK1124071A1 (en) 2009-07-03
IL188222A (en) 2015-11-30
AU2006261445A1 (en) 2006-12-28
EP2380589A3 (en) 2012-09-12
CN102836425A (zh) 2012-12-26
IL222915A0 (en) 2012-12-31
ES2647070T3 (es) 2017-12-19
IL222914A0 (en) 2012-12-31
EP2163255A1 (en) 2010-03-17
EP2163255B1 (en) 2017-08-09
HK1179855A1 (zh) 2013-10-11
EP2380589A2 (en) 2011-10-26
EP2380590A2 (en) 2011-10-26
CN102836425B (zh) 2015-08-19
KR101188045B1 (ko) 2012-10-05

Similar Documents

Publication Publication Date Title
KR101035053B1 (ko) 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신
US10519202B2 (en) Tuberculosis TB vaccine to prevent reactivation
EP1523331B1 (en) Therapeutic tb vaccine
WO2005061534A2 (en) Improved tuberculosis vaccines
US7935354B2 (en) Generation of new BCG vaccine strains protecting against the establishment of latent Mycobacterium tuberculosis infection and reactivation from the latent or persistent state
CN101248084B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
AU2013206297A1 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
CIPO Prophylactic GP studies
HK1124071B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1179855B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20140425

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20150424

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20170412

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20180425

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210510

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210510